Since then, several new agents and many different regimens consisting of various combinations of chemotherapy and radiotherapy have been studied in large clinical trials [ 1– 5].
At the same time, our understanding of oestrogen receptor biology and the consequence of ligand interaction in different tissues is expanding, which should allow us to maximize the properties of these various new endocrine agents which are now available.
The development of novel models of drug development that allow the assessment of the expression of these genes, particularly within the presurgical setting, offers major opportunities to assess the potential of the various new targeted agents to be combined with endocrine therapy.
Various newer uterotonic agents have been evaluated, 15 16 17 18 19 20 and the recent Canadian guidelines recommend the use of carbetocin (a long acting synthetic oxytocic) instead of oxytocin at caesarean section.
With various new IL-6 related IL-6 relatedagentherapeuticipeline, we hagentsveloped a multincale systhe model that integrates current knowledge about the biology of IL-6–mediated immune respipeline Crohn's and used it for mechanistic assessment and comparison of several proposed therapeutic strategies.
In addition, the advances in the development of many molecular-targeted agents provide opportunities to explore various new combination therapies containing both cytotoxic and molecular-targeted agents for patients with CUP.
A number of new agents are in various stages of clinical evaluation.
Several clinical trials have since investigated new agents, alone and in combination, for various cancers.
In the present study, we have designed a workflow by integrating various ligand-based and structure-based approaches to discover new agents active against DNMT1.
As a consequence, various new osteosarcoma therapies have been investigated worldwide, with many clinical trials performed on novel agents.
Using haloperidol as a scaffold, new agents were designed to investigate the structural contributions of various groups to binding at CNS receptors associated with atypical antipsychotic pharmacology.
